Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.06 AUD | 0.00% | -3.23% | -25.00% |
16/04 | Amplia Therapeutics to Raise AU$4.3 Million for Cancer Trials, Drug Capsule Manufacturing | MT |
27/03 | Amplia Concludes Phase I Trials of Anti-Cancer Drug; Prepares for Phase II | MT |
Business Summary
Sales per Business
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Focal Adhesion Kinase
100.0
%
| 0 | nan % | 0 | 100.0 % | - |
Sales per region
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Australia
100.0
%
| 0 | nan % | 0 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Founder | - | 31/00/31 | |
Tim Luscombe
DFI | Director of Finance/CFO | - | 25/23/25 |
Rhiannon Jones
COO | Chief Operating Officer | - | 01/21/01 |
Charlotte Mulder
PRN | Corporate Officer/Principal | - | - |
Mark Devlin
PRN | Corporate Officer/Principal | - | - |
Andrew Cooke
SEC | Corporate Secretary | 62 | 11/13/11 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Andrew Cooke
SEC | Corporate Secretary | 62 | 11/13/11 |
Robert Peach
BRD | Director/Board Member | 68 | 02/15/02 |
Warwick Tong
CHM | Chairman | - | 04/18/04 |
Founder | - | 31/00/31 | |
Jane Bell
BRD | Director/Board Member | - | 12/21/12 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 271,608,953 | 230,720,249 ( 84.95 %) | 0 | 84.95 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
-25.00% | 7.69M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- ATX Stock
- Company Amplia Therapeutics Limited